StockData
Intensity Therapeutics, Inc. logo

Intensity Therapeutics, Inc. (INTS) stock

INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$3.28+0.19 (+6.15%)

Close on Nov 11, 2026Market cap $10.71MP/E –Yield –

Intensity Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Intensity Therapeutics's enterprise value was $455.97K on Nov 3, 2026, against $12.49M a year earlier. Over the last 4 years it ranged from $216.12K to $101.84M, with a median of $18.19M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 3, 2026$455.97K-96.5%
2025Dec 31, 2025$13.03M-39.7%
2024Dec 31, 2024$21.62M-78.8%
2023Dec 29, 2023$101.84M–

More Intensity Therapeutics figures

See a number that looks wrong?